Peroxisome proliferator-activated receptor (PPAR) modulators offer potential benefits for the treatment of obesity and its associated complications but their development has been complicated by biological, technical, and regulatory challenges. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.